213 related articles for article (PubMed ID: 31754924)
1. Economic evaluation of meningococcal vaccines: considerations for the future.
Christensen H; Al-Janabi H; Levy P; Postma MJ; Bloom DE; Landa P; Damm O; Salisbury DM; Diez-Domingo J; Towse AK; Lorgelly PK; Shah KK; Hernandez-Villafuerte K; Smith V; Glennie L; Wright C; York L; Farkouh R
Eur J Health Econ; 2020 Mar; 21(2):297-309. PubMed ID: 31754924
[TBL] [Abstract][Full Text] [Related]
2. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
Beck E; Klint J; Neine M; Garcia S; Meszaros K
Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
[TBL] [Abstract][Full Text] [Related]
4. Methodological concerns with economic evaluations of meningococcal vaccines.
Kauf TL
Pharmacoeconomics; 2010; 28(6):449-61. PubMed ID: 20465314
[TBL] [Abstract][Full Text] [Related]
5. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Si S; Zomer E; Fletcher S; Lee J; Liew D
Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.
Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T
Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
10. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada.
Huang L; Mauskopf J; Farkouh R; Masaquel C
Expert Rev Vaccines; 2021 Jan; 20(1):59-72. PubMed ID: 33455487
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
De Wals P; Zhou Z
Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain].
Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J
Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044
[TBL] [Abstract][Full Text] [Related]
13. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
Christensen H; Trotter CL; Hickman M; Edmunds WJ
BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
[TBL] [Abstract][Full Text] [Related]
15. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
Nwogu IB; Jones M; Langley T
Vaccine; 2021 Apr; 39(16):2201-2213. PubMed ID: 33744052
[TBL] [Abstract][Full Text] [Related]
18. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation.
Skull SA; Butler JR; Robinson P; Carnie J
Int J Epidemiol; 2001 Jun; 30(3):571-8; discussion 578-9. PubMed ID: 11416085
[TBL] [Abstract][Full Text] [Related]
19. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.
Miller MA; Wenger J; Rosenstein N; Perkins B
Pediatr Infect Dis J; 1999 Dec; 18(12):1051-9. PubMed ID: 10608623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
